HibTITER (diphtheria crm197 protein conjugate) / Nuron Biotech, Tanabe Pharma - LARVOL DELTA

Covalent modification of Keap1 Cys489 by NU6300 activates Nrf2 signaling and suppresses NLRP3 inflammasome-mediated pyroptosis. (PubMed, J Pharm Anal) - "In vivo, NU6300 exhibits potent antioxidant and anti-inflammatory protection against acetaminophen (APAP)-induced acute liver injury in mice. Collectively, these findings demonstrate that NU6300 is a novel Nrf2 activator and offers a promising therapeutic strategy for pyroptosis-driven inflammatory diseases."

Journal • Hepatology • Inflammation • Liver Failure • KEAP1 • NLRP3

Progress in small-molecule inhibitors of gasdermin D. (PubMed, Eur J Med Chem) - "Examples include small-molecule drugs targeting Cys191/192 such as DMF, DSF, NSA, and NU6300, as well as molecules targeting other residues like mafenide, GI-Y1, and GI-Y2. Optimizing specificity and exploring disease-specific applications remain pivotal to advancing these inhibitors as therapeutic agents. Current research focuses on developing clinically translatable, highly effective, and safe GSDMD-targeted therapies through structure-guided optimization, drug repurposing, innovations in precision delivery systems, and synergistic mechanism approaches."

Journal • Review • Immunology • Infectious Disease • Inflammation • Oncology • Septic Shock

Adverse outcome detection of childhood administered thimerosal-free HibTITER®. (PubMed, Int J Risk Saf Med) - "Incidence of 19 different medical conditions was significantly higher compared to the control group who received other HIB vaccine formulations. These results were corroborated using the VAERS database, and have profound medical implications for the estimated 35 million Americans between the ages of 16 and 33 who received the vaccine."

Adverse events • Journal • Asthma • Dermatology • Gastrointestinal Disorder • Immunology • Infectious Disease • Influenza • Otorhinolaryngology • Pediatrics • Pulmonary Disease • Respiratory Diseases • Tuberculosis

NU6300 covalently reacts with cysteine-191 of gasdermin D to block its cleavage and palmitoylation. (PubMed, Sci Adv) - "In vivo studies further demonstrate the efficacy of NU6300 in ameliorating dextran sodium sulfate-induced colitis and improving survival in lipopolysaccharide-induced sepsis. Overall, these findings highlight the potential of NU6300 as a promising lead compound for the treatment of inflammatory diseases."

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Septic Shock • NLRP3